Herbst RS, Garon EB, Kim DW, Cho BC, et al. 5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death Ligand 1-Positive Advanced Non-Small-Cell Lung Cancer. J Thorac Oncol 2021 May 25. pii: S1556-0864(21)02172.
PMID: 34048946